Huapont Life Science Co (SZSE:002004) EBIT : ¥1,155 Mil (TTM As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Huapont Life Science Co EBIT?

Huapont Life Science Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥371 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,155 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Huapont Life Science Co's annualized ROC % for the quarter that ended in Mar. 2024 was 4.14%. Huapont Life Science Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 13.23%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Huapont Life Science Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 8.63%.

Huapont Life Science Co EBIT Historical Data

The historical data trend for Huapont Life Science Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huapont Life Science Co EBIT Chart

Huapont Life Science Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

1,714.79

1,726.16

1,742.92

2,056.71

1,236.09

Huapont Life Science Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															452.11	516.04	382.98	-115.04	370.81

Competitive Comparison of Huapont Life Science Co's EBIT

For the Agricultural Inputs subindustry, Huapont Life Science Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Huapont Life Science Co's EV-to-EBIT Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, Huapont Life Science Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Huapont Life Science Co's EV-to-EBIT falls into.

Huapont Life Science Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,155 Mil.

Huapont Life Science Co (SZSE:002004) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Huapont Life Science Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	1412.904 * ( 1 - 24.38% )	/	( (25264.834	+	26290.205)	/ 2 )
=	1068.4380048	/	25777.5195
=	4.14 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	30727.397	-	4708.915	-	( 4413.135	-	max(0, 10633.752	-	11387.4	+	4413.135	))
=	25264.834

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	31479.044	-	4316.595	-	( 4901.933	-	max(0, 11278.182	-	12150.426	+	4901.933	))
=	26290.205

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Huapont Life Science Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1483.22	/	( ( (10024.471 + max(807.906, 0))	+	(10025.532 + max(1566.134, 0)) )	/	2 )
=	1483.22	/	( ( 10832.377	+	11591.666 )	/	2 )
=	1483.22	/	11212.0215
=	13.23 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1502.404	+	2674.606	+	1570.893)	-	(4708.915	+	0	+	231.082)
=	807.906

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1947.18	+	2507.214	+	1595.767)	-	(4316.595	+	0	+	167.432)
=	1566.134

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Huapont Life Science Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	1154.784	/	13380.125
	=	8.63 %

Huapont Life Science Co EBIT Related Terms

Thank you for viewing the detailed overview of Huapont Life Science Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Huapont Life Science Co (SZSE:002004) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Huapont Life Science Co Ltd (SZSE:002004) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 69, Renhe Xingguang Avenue, Yubei District, Chongqing, CHN, 401121

Website

http://www.huapont.com.cn

Huapont Life Science Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. In addition, the company is also engaged in the agrochemical business and medical business. The agrochemical department is mainly engaged in the research and development, production, sales, and technical services of pesticide intermediates, original drugs, and preparations.

Executives

Zhang Hai An	Directors, executives
Wang Rong	Director
Yu Jun Tian	Director
Zhang Song Shan	Directors, executives
Chen Zhi	Securities Affairs Representative
Jiang Kang Wei	Director
Lv Li Ming	Director
Li Sheng Xue	Director
Luo Da Lin	Supervisors
Li Zhi	Directors, executives
Tian Song Min	Executives
Wu Bi Zhong	Director
Yu Yun Jian	Supervisors
Gu Chuan Wei	Supervisors

Huapont Life Science Co (SZSE:002004) Headlines

No Headlines